SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Patients with asthma and T2 diabetes using SGLT2 inhibitors have a significantly decreased mortality risk within 30 days of an asthma exacerbation.

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Sean Virani, MD, lead author of the new guidelines and president of the CCS, explained that the guidelines use the term ...

Deborah J. Wexler, MD, MSc, and colleagues reviewed recent shifts in diabetes care, such as SGLT2i and GLP-1 RA medications.

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Treatment with TNF-α inhibitors may be safer than IL-6 inhibitors in terms of cardiovascular outcomes when managing patients with RA and T2D.

Opinion - In South Africa, two people can live with the same chronic condition yet face vastly different realities.

ON THIS PAGEDiabetes and HydrationCKD and HydrationExpert RecommendationsHydration and MedicationDehydration Warning ...

The proportion of participants achieving HbA1c < 7.0% and a =10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide ...